loading
Hoth Therapeutics Inc stock is traded at $1.23, with a volume of 106.44K. It is down -3.13% in the last 24 hours and up +9.73% over the past month. Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
See More
Previous Close:
$1.28
Open:
$1.27
24h Volume:
106.44K
Relative Volume:
0.10
Market Cap:
$16.25M
Revenue:
-
Net Income/Loss:
$-7.51M
P/E Ratio:
-0.9318
EPS:
-1.32
Net Cash Flow:
$-8.02M
1W Performance:
-6.06%
1M Performance:
+9.73%
6M Performance:
-3.88%
1Y Performance:
+48.56%
1-Day Range:
Value
$1.22
$1.28
1-Week Range:
Value
$1.22
$1.38
52-Week Range:
Value
$0.58
$3.80

Hoth Therapeutics Inc Stock (HOTH) Company Profile

Name
Name
Hoth Therapeutics Inc
Name
Phone
(646)756-2997
Name
Address
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Name
Employee
3
Name
Twitter
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
HOTH's Discussions on Twitter

Compare HOTH with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
HOTH
Hoth Therapeutics Inc
1.23 16.91M 0 -7.51M -8.02M -1.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
466.99 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
565.50 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.26 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
595.19 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
297.82 31.54B 3.81B -644.79M -669.77M -6.24

Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-15-19 Initiated The Benchmark Company Speculative Buy

Hoth Therapeutics Inc Stock (HOTH) Latest News

pulisher
12:46 PM

When is Hoth Therapeutics Inc. stock expected to show significant growthDynamic portfolio growth - jammulinksnews.com

12:46 PM
pulisher
Jul 27, 2025

How strong is Hoth Therapeutics Inc. company’s balance sheetSuperior trading gains - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What catalysts could drive Hoth Therapeutics Inc. stock higher in 2025Maximize portfolio growth with strategic plans - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What is the dividend policy of Hoth Therapeutics Inc. stockInvest confidently with data-driven strategies - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What institutional investors are buying Hoth Therapeutics Inc. stockFind market-beating stocks for your portfolio - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Why is Hoth Therapeutics Inc. stock attracting strong analyst attentionGrow your wealth steadily and securely - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What is the risk reward ratio of investing in Hoth Therapeutics Inc. stockGet high-impact stock recommendations now - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 26, 2025

What makes Hoth Therapeutics Inc. stock price move sharplyFree Growth Investment Group - metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

What analysts say about Hoth Therapeutics Inc. stockFree Wealth Management Insights - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Hoth Therapeutics Inc. stock priceFree Trading Strategy Suggestions - Autocar Professional

Jul 25, 2025
pulisher
Jul 24, 2025

Is Hoth Therapeutics Inc. a good long term investmentTriple returns potential - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 23, 2025

Hoth Therapeutics Inc. Stock Analysis and ForecastHigh-yield trading alerts - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Hoth Therapeutics shares fall 1.52% intraday after signing VA research deal to advance GDNF as breakthrough therapy for obesity and fatty liver. - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

Hoth Therapeutics partners with VA to test GDNF therapy for obesity By Investing.com - Investing.com South Africa

Jul 22, 2025
pulisher
Jul 22, 2025

Hoth Therapeutics partners with VA to test GDNF therapy for obesity - Investing.com Australia

Jul 22, 2025
pulisher
Jul 22, 2025

New Weight Loss Drug Challenger GDNF Takes On Semaglutide in Landmark VA Obesity Study - Stock Titan

Jul 22, 2025
pulisher
Jul 22, 2025

Why Hoth Therapeutics Inc. stock attracts strong analyst attentionElite Investor Club - Newser

Jul 22, 2025
pulisher
Jul 15, 2025

How Hoth Therapeutics Inc. stock performs during market volatilitySwing Trade Signals - Newser

Jul 15, 2025
pulisher
Jul 05, 2025

Hoth Therapeutics (NASDAQ:HOTH) Upgraded by Wall Street Zen to Hold Rating - Defense World

Jul 05, 2025
pulisher
Jun 30, 2025

Traumatic Brain Injury Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

Jun 30, 2025
pulisher
Jun 25, 2025

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market | Daily Courier - FinancialContent

Jun 25, 2025
pulisher
Jun 24, 2025

Hoth Therapeutics Advances HT-001 for Cancer Treatment - TipRanks

Jun 24, 2025
pulisher
Jun 24, 2025

HT-001's Breakthrough in Oncology Supportive Care: A Game-Changer for Hoth Therapeutics? - AInvest

Jun 24, 2025
pulisher
Jun 24, 2025

Hoth Therapeutics stock rises after positive Phase 2a trial results By Investing.com - Investing.com India

Jun 24, 2025
pulisher
Jun 23, 2025

Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy - PR Newswire

Jun 23, 2025
pulisher
Jun 20, 2025

Hoth Therapeutics Regains Nasdaq Compliance on June 18 - TipRanks

Jun 20, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics reports positive preclinical safety data for HT-KIT By Investing.com - Investing.com South Africa

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics Regains Nasdaq Compliance - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics regains Nasdaq compliance after meeting minimum bid - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics Just Cleared Critical Nasdaq Hurdle: What This Means for Its $1B+ Biotech Pipeline - Stock Titan

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT Dose-Dependent Liver Activity with No Observed Toxicity Supports Ind Pathway - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics reports positive preclinical safety data for HT-KIT - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics (HOTH) Reports Promising Preclinical Outcomes for Cancer Drug | HOTH Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Cancer Drug Breakthrough: Hoth's HT-KIT Achieves Perfect Safety Profile Ahead of Clinical Trials - Stock Titan

Jun 18, 2025

Hoth Therapeutics Inc Stock (HOTH) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.29
price down icon 0.49%
$36.97
price up icon 0.79%
$103.09
price down icon 0.76%
$27.91
price down icon 2.53%
$113.69
price down icon 1.41%
biotechnology ONC
$297.78
price up icon 2.20%
Cap:     |  Volume (24h):